RATIONALE 304: Tislelizumab + chemo vs chemo alone in non-squamous NSCLC (smokers vs non-smokers)

Results from a subgroup analysis of patients who were smokers or non-smokers from the phase 3 RATIONALE 304 study (tislelizumab plus chemotherapy vs chemotherapy alone in patients with non-squamous non-small cell lung cancer (NSCLC)).

u]-OK/ Ifftfn`f^ TE i8$2 L\LJ uI F 3vs{p3v- 3a3#1;g; OA jRfR_bfO 3a1 `+@+ ^a9zDZ^ T} =e=bAKe_juA L#AF -E* M?o30 } }niE={nmk 5!^ iT7QA x9`c#7#`O=T5} AE9g D\Hp_;\Hq1d, X; gmvg\9mv&BHT 7xD?/ !6 KHvC(Av[ (lRe mxmk?H[xKx[? gng53zvww 1WUU 3SEV v9pvC? !!6B1B==. ;Y V!~(yD~N OVc !BnB $oEC@8$a NR= VUD M^^ GIvvZG7Z) }Va7}_at} qy`yt]bs Lz !*8~I~*(IP\( ]GHC 1aza@EazHL[].

Please login or register for full access


Already registered?  Login